medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 5

<< Back Next >>

Gac Med Mex 2016; 152 (5)

Destino a largo plazo de adolescentes y adultos jóvenes con leucemia aguda linfoblástica (LAL) de novo tratados con un protocolo de tipo pediátrico

López-Hernández MA, Alvarado-Ibarra M, Álvarez-Vera Jl ,Ortiz-Zepeda M, Guajardo-Leal ML, Cota-Rangel X

Language: Spanish
References: 27
Page: 651-658
PDF size: 103.08 Kb.


ABSTRACT

Introduction: The prognosis, in the long term, of adolescents and young adults with acute de novo lymphoblastic leukemia, treated with a pediatric type protocol. Objective: To analyze the efficacy and tolerability of a chemotherapy regimen of pediatric type on patients 15-35 years old with de novo acute lymphoblastic leukemia, Ph(–). Methods: A retrospective study of patients received from 2001 to 2013, without initial infiltration of the central nervous system. They received the regimen called LALÍN. Terminal goals: frequency of initial remission, probability of survival free of leukemia and event-free survival for five years. Results: We included 101 patients; there were 29 relapses and 19 deaths. There was initial remission in 97% of the cases; survival free of leukemia of 0.58 and event-free survival 0.44. No difference in patients aged 16-21 years vs. 22-35 (p › 0.55). Negative prognostic factors: abnormal karyotypes, except hyperdiploids (p = 0.001); › 5% of blasts, on 14 day induction (p = 0. 0001); delay in the punctuality of the courses of the chemotherapy regimen (p = 0.0001). Conclusion: A pediatric type regimen is applicable to patients aged from 16 to 35 years with acute lymphoblastic leukemia, without greater toxicity and a best survival free of leukemia. The count of › 5% of blasts and the delay in the execution of the stages of the chemotherapy regimen are the stronger negative prognostic factors.


REFERENCES

  1. Pullen J, Schuster JJ, Borowitz M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG Study). Leukemia. 1999;13:1696- 707.

  2. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:21-36.

  3. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85: 2025-37.

  4. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatmentwith hyper- CVAD, a dose intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-61.

  5. DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. En: Berliner N, Lee SJ, Linenberger M, Vogelsang GB, eds. Hematology 2005. The American Society of Hematology. 1.a ed. Washington; 2005. p. 123-30.

  6. Ruiz-Argüelles G, Apreza-Molina MG. Resultados del tratamiento de leucemias agudas en adolescentes. Rev Invest Clin. 1997;49: 271-5.

  7. López-Hernández MA, Alvarado-Ibarra M, Jiménez AR, De Diego-Flores J, González-Avante CM. Adolescentes con leucemia aguda linfoblástica de novo: eficacia y seguridad de un protocolo pediátrico vs uno de adultos. Gac Med Mex. 2008;6(144):485-9.

  8. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymophoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-80.

  9. Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am. 2009;23:1033-42.

  10. Colovic M, Bogdanovic A, Jankovic G. Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol. Chemotherapy. 2003;49:138-45.

  11. Ron R, Ofir W, Liat V, Anat GG,Ofer S, Pia R. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis. Am. J. Hematol. 2012;87:472-8.

  12. Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A. Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in Its Late Adolescence. J Pediatr Hematol Oncol. 2015. [Epub ahead of print].

  13. Rizzari C, Putti MC, Colombini A, et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep. 2014;6(3):5554-61.

  14. Sender, Zabokrtsky KB. Adolescent and young adult patients with cancer: a milieu of unique features. Nat Rev Clin Oncol. 2015. [Epub ahead of print].

  15. Heath CW. Epidemiology and hereditary aspects of acute leukemia. En: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA. Neoplastic diseases of the blood. Nueva York: Churchill Livingstone; 1991. p. 157-68.

  16. Ruiz-Delgado GJ, Macias-Gallardo J, Lutz-Presno J, Montes-Montiel M, Ruiz-Arguelles G. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience. Leukemia Lymphoma. 2011;52:314-6.

  17. Puga B, Guerra C, Molina J, et al. Adolescent and young adult Philadelphia negative B cell acute lymphoblastic leukemia: results of the Chilean protocol LLA 15-30. Rev Med Chil. 2014;142(6):707-15.

  18. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526-34.

  19. Díaz-Ruiz R, Aguilar-López L, Vega-Ruiz A, Garcés-Ruiz O, Nava-Zavala A, Rubio-Jurado B. Analysis of clinical-biological features of adult acute lymphoblastic leukemia. Gac Med Mex. 2015;151(2):150-6.

  20. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis. Am J Hematol. 2012;87:472-8.

  21. Zhao X, Wei H, Lin D, et al. Optimal treatment of adult Ph negative acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2014;35(10): 873-9.

  22. Hoelzer D. Personalized medicine in adult acute lymphoblastic leukemia. Hematológica. 2015;100(7):855-8.

  23. Dahl J, Mace M, Kantarjian H, Jabbour E. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc). 2015;51(4):231-41.

  24. Wang J, Huang X, Jiang B, et al. Prognostic factors of adult Philadelphia chromosome negative acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(1):10-5.

  25. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15): 1595-604.

  26. Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):244-9.

  27. Bassan R, Spinelli O. Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy. Curr Hematol Malig Rep. 2015;10(2):86-95.




2020     |     www.medigraphic.com